Amgen Launches First International Oncology Website

By Amgen, PRNE
Wednesday, June 8, 2011

ZUG, Switzerland, June 9, 2011 -

Amgen announced today the launch of its first oncology website for the
international oncology community outside the United States.
amgenoncology-international.com launched at the European Hematology Congress
in London, and provides comprehensive oncology scientific information and
clinical resources for oncology healthcare professionals worldwide.

The site includes information on the innovative science undertaken by
Amgen in oncology, treatment tools, clinical trials, regulatory authority
approved product information, links to patient resources and the latest Amgen
oncology news.

"The launch of this website is an exciting development and reinforces our
commitment to furthering science and sharing information in the oncology
area," said Tom Lillie, International Development Executive Medical Director.
"Amgen has a comprehensive and pioneering approach to addressing cancer, and
with the launch of this site, we aim to share our progress and work, as well
as support the international oncology community we work in."

Amgen's comprehensive approach to addressing cancer is pursued through
the scientific exploration of numerous biologic pathways and multiple
scientific modalities. Amgen also collaborates with the oncology, hematology
and urology communities to provide patient education and support and ensure
that the appropriate patients have access to its medicines.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping millions of people around the world
in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease, and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our pioneering
science and vital medicines, visit www.amgen.com.

Forward-Looking Statements

This statement contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to
differ materially from those described. All statements, other than statements
of historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
by Amgen, including Amgen's most recent annual report on Form 10-K and most
recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's
most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business. Unless otherwise
noted, Amgen is providing this information as of June 9, 2011 and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may
differ materially from those we project. Discovery or identification of new
product candidates or development of new indications for existing products
cannot be guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product candidate
or development of a new indication for an existing product will be successful
and become a commercial product. Further, preclinical results do not
guarantee safe and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modelled by computer or cell culture systems or animal models. The
length of time that it takes for us to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and we
expect similar variability in the future. We develop product candidates
internally and through licensing collaborations, partnerships and joint
ventures. Product candidates that are derived from relationships may be
subject to disputes between the parties or may prove to be not as effective
or as safe as we may have believed at the time of entering into such
relationship. Also, we or others could identify safety, side effects or
manufacturing problems with our products after they are on the market. Our
business may be impacted by government investigations, litigation and
products liability claims. We depend on third parties for a significant
portion of our manufacturing capacity for the supply of certain of our
current and future products and limits on supply may constrain sales of
certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement
policies imposed by third-party payers, including governments, private
insurance plans and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international trends
toward managed care and healthcare cost containment as well as U.S.
legislation affecting pharmaceutical pricing and reimbursement. Government
and others' regulations and reimbursement policies may affect the
development, usage and pricing of our products. In addition, we compete with
other companies with respect to some of our marketed products as well as for
the discovery and development of new products. We believe that some of our
newer products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Our products
may compete against products that have lower prices, established
reimbursement, superior performance, are easier to administer, or that are
otherwise competitive with our products. In addition, while we routinely
obtain patents for our products and technology, the protection offered by our
patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of our ability
to obtain or maintain patent protection for our products or product
candidates. We cannot guarantee that we will be able to produce commercially
successful products or maintain the commercial success of our existing
products. Our stock price may be affected by actual or perceived market
opportunity, competitive position, and success or failure of our products or
product candidates. Further, the discovery of significant problems with a
product similar to one of our products that implicate an entire class of
products could have a material adverse effect on sales of the affected
products and on our business and results of operations.

The scientific information discussed in this statement related to our
product candidates is preliminary and investigative and is not part of the
labeling approved by the U.S. FDA or the European Medicines Agency (EMA) for
the products. The products are not approved for the investigational use(s)
discussed in this news release, and no conclusions can or should be drawn
regarding the safety or effectiveness of the products for these uses. Only
the FDA, EMA or other applicable regulatory bodies can determine whether the
products are safe and effective for these uses. Healthcare professionals
should refer to and rely upon the approved labeling for the products, and not
the information discussed in this statement.

E.U. media, Carrie Deverell, +41 41 3690 308, or U.S. media, Christine Regan, +1-805-447-5476, both of Amgen

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :